Clinical trials, particularly randomized controlled trials, are widely regarded as the gold standard for evaluating the effectiveness and safety of health care interventions. 1,2 Notably, as the ...

CDK 4/6 inhibitors (CDK4/6i) remain part of the standard first-line treatment for patients with hormone receptor–positive metastatic breast cancer, offering demonstrable improvements in both ...

Long-Term Follow-Up of E3311, an ECOG-ACRIN Cancer Research Group Phase II Trial of Transoral Surgery and Risk-Based Adjuvant Treatment in Human Papillomavirus–Initiated Oropharynx Cancer Despite ...

Breast cancer is the most common cancer diagnosed in women, making it the second most commonly diagnosed cancer in the world. 1,2 About 2.3 million new breast cancer cases and 685,000 deaths occurred ...

Background: NIVO + RELA fixed-dose combination (FDC), compared with NIVO alone, demonstrated a clinically meaningful benefit to progression-free survival (HR 0.79, 95% CI 0.66–0.95) and overall ...

Pancreatic cancer is soon to be the second leading cause of cancer-related death in the United States. 1 Despite this reality, it is undeniable that there have been improvements in the management of ...

For the purpose of this paper, we define oncology rehabilitation as services provided by licensed medical providers (eg, physical or occupational therapists, physical medicine and rehabilitation ...

Frustrations regarding the costs and difficulties with parking at hospitals is a common concern voiced by patients, families, and healthcare providers. Transportation barriers to receiving cancer care ...

Background: PV is characterized by red blood cell overproduction. Rusfertide is a subcutaneous (SC), self-injected, first-in-class peptide hepcidin mimetic that decreases erythrocytosis. VERIFY ...

This study evaluated three LLMs (GPT-3.5-turbo-0125, GPT-4-turbo, and GPT-4o) using drug names from HemOnc ontology. The assessment included 367 generic-to-brand and 2,516 brand-to-generic pairs, ...

The National Cancer Institute defines rare cancer as a cancer with an incidence rate <15 per 100,000 people; recently, the term “ultra-rare cancer” was defined as cancer with an incidence rate <1 × 10 ...

Hepatocellular carcinoma (HCC) is a lethal malignancy that is subtle neither in its clinical presentation nor in its aggressive course. Numerous diagnostic guidelines have focused on noninvasive ...